Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on 1 Naphthylamine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101475489B reveals a safer hydrogenation route for naphthylamine derivatives, offering significant cost reduction in pharmaceutical intermediate manufacturing through catalyst reuse.
Patent CN111410656A discloses a novel CuCN-catalyzed cyclization for isoquinolinones. This method offers mild conditions, high yields, and significant cost reduction potential for pharmaceutical manufacturing.
Novel continuous flow photo-thermal synthesis method ensures high purity and scalable production for pharmaceutical intermediates reducing lead time significantly.
Patent CN1213991C reveals a copper-catalyzed route for high-purity sertraline intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN117003678B reveals green iodide-catalyzed route for naphthylamine derivatives. Offers significant cost reduction and supply reliability for pharmaceutical intermediates manufacturing globally without transition metals.
Patent CN111410656B details a novel copper-catalyzed route to isoquinolinones, offering cost reduction in pharmaceutical intermediate manufacturing and scalable production capabilities.
Patent CN116478052B reveals copper-catalyzed synthesis for high-purity 1-naphthylamine derivatives. Offers scalable production and cost reduction for pharmaceutical intermediate manufacturing supply chains.
This patent details a copper-catalyzed synthesis for 1-naphthylamine derivatives offering high yields. It enables cost reduction and scalable manufacturing for reliable pharmaceutical intermediate suppliers globally.
Novel copper-silver catalyzed method enables direct synthesis of high-purity phosphonylated naphthylamines with mild conditions and scalable manufacturing advantages.
Novel copper-silver catalyzed synthesis enables mild condition production of high-purity pharmaceutical intermediates with simplified purification and enhanced supply chain reliability.
Patent CN102276376B introduces an efficient synthesis route eliminating chiral resolution, enhancing purity and reducing supply chain costs for pharmaceutical intermediates.
Struggling with toxic C-Se bond formation? Discover green photoinduced catalysis for 1-phenylseleno-naphthylamine synthesis. Find reliable suppliers for high-purity intermediates.